首页> 外文OA文献 >Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate

【2h】

Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate

机译：用Secukinumab作为一种抗风湿药物的抗风湿药物治疗抗风湿药物的治疗策略与活跃的轴向脊椎腹膜炎患者的标准治疗：随机开放标签III研究的协议，安安加酸盐

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Denis Poddubnyy; Ludwig Hammel; Marvin Heyne; Justyna Veit; Claudia Jentzsch; Xenofon Baraliakos;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial [J] . van der Heijde Desiree, Wei James Cheng-Chung, Dougados Maxime, The Lancet . 2018,第10163期

机译：Ixekizumab，一种白细胞介素-17A拮抗剂，治疗脊柱膜炎或射线摄影轴向脊椎动物，以前未经生物减少抗风湿药物（Coast-V）：16周的第3期随机，双盲，主动控制的结果和安慰剂对照试验
2. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, Active Axial Spondyloarthritis: Results from a 6-month, randomised, open-label follow-up study, INFAST Part 2 [J] . SieperJ., LenaertsJ., WollenhauptJ., Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第1期

机译：早期，活动性轴突性脊柱关节炎患者采用萘普生或不进行治疗可维持无生物学缓解：INFAST第2个月的随机开放性随访研究，为期6个月
3. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial [J] . Genovese Mark C., Fleischmann Roy, Combe Bernard, The Lancet . 2018,第10139期

机译：upadacitinib在活性类风湿性关节炎患者对生物疾病改性抗风湿药物难治的安全性和有效性（选择 - 超越）：双盲，随机对照第3阶段试验
4. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study AScalate [O] . Denis Poddubnyy, Ludwig Hammel, Marvin Heyne, 2020

机译：用Secukinumab作为一种抗风湿药物的抗风湿药物治疗抗风湿药物的治疗策略与活跃的轴向脊椎腹膜炎患者的标准治疗：随机开放标签III研究的协议安安加酸盐
5. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial [O] . Désirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, 2018

机译：Ixekizumab，一种白细胞介素-17A拮抗剂，治疗脊柱膜炎或射线照相轴向脊椎炎，以前未经治疗生物疾病改性抗风湿药物（Coast-V）：16周的一期随机，双盲，活性 - 控制和安慰剂对照试验

Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate

著录项

引文网络

相似文献

相关主题

期刊订阅